Hospital
ST Mary Medical Center INC
ST Mary Medical Center INC was paid $23.44M by Medicaid between Jan 2018 and Dec 2024, across 151 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoST MARY MEDICAL CENTER INC
HOBART, IN 46342
HOBART, IN 46342
33aNPI1558463745assigned 09/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.44M
24GClaims534,980
24DCodes billed151
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#18 of 69
Median peer was paid$9.76M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,850 | $1.06M | |
| 2019 | 56,414 | $1.70M | |
| 2020 | 52,529 | $1.84M | |
| 2021 | 87,030 | $3.85M | |
| 2022 | 103,907 | $5.13M | |
| 2023 | 92,500 | $5.42M | |
| 2024incomplete | 77,750 | $4.43M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 33,767 | 28,483 | $4.99M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 23,476 | 19,607 | $3.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.5% | 14,881 | 12,910 | $2.23M |
| 71046 | Radiologic examination, chest; 2 views | 8.5% | 14,806 | 12,573 | $1.99M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.5% | 20,938 | 17,017 | $1.30M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5.4% | 6,095 | 5,103 | $1.25M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.2% | 9,572 | 8,427 | $976K |
| 71045 | Radiologic examination, chest; single view | 3.8% | 7,637 | 6,412 | $898K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 1,813 | 1,541 | $747K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.9% | 11,088 | 9,223 | $671K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.6% | 11,842 | 9,928 | $620K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 5,014 | 4,162 | $535K |
139 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 1,934 | $371K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.5% | 360 | $348K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.4% | 3,672 | $318K |
| 80053 | Comprehensive metabolic panel | 1.0% | 41,732 | $236K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 487 | $230K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,130 | $180K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 40,664 | $169K |
| 36415 | Collection of venous blood by venipuncture | <1% | 75,793 | $155K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 116 | $120K |
| 87631 | <1% | 2,209 | $117K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,796 | $115K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,953 | $92K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,273 | $86K |
| 84484 | <1% | 9,948 | $80K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 252 | $74K |
| 81025 | <1% | 12,906 | $72K | |
| 81001 | <1% | 30,373 | $56K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 32 | $46K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,760 | $44K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,200 | $41K |
| 83690 | <1% | 10,962 | $37K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 313 | $37K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,454 | $36K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,018 | $33K |
| 83735 | <1% | 8,981 | $33K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 933 | $33K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 290 | $30K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 191 | $30K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,144 | $29K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,145 | $29K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $29K |
| 80050 | General health panel | <1% | 162 | $27K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,680 | $27K |
| 87040 | <1% | 2,972 | $26K | |
| 93296 | <1% | 235 | $25K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,624 | $24K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 179 | $20K |
| 85027 | <1% | 5,311 | $20K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 296 | $19K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,095 | $19K |
| 85730 | <1% | 5,409 | $18K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 803 | $17K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 817 | $14K |
| 85610 | <1% | 6,066 | $14K | |
| 88142 | <1% | 1,335 | $13K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 957 | $13K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 114 | $12K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 110 | $12K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 599 | $11K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 694 | $11K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 33 | $11K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 449 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,208 | $9K |
| 84439 | <1% | 1,589 | $8K | |
| 68841 | <1% | 62 | $8K | |
| 83605 | <1% | 1,162 | $7K | |
| 74018 | <1% | 41 | $7K | |
| 86140 | <1% | 2,187 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,362 | $7K |
| 84481 | <1% | 610 | $6K | |
| 80061 | Lipid panel | <1% | 683 | $6K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 19 | $5K |
| 82565 | <1% | 1,645 | $5K | |
| 82077 | <1% | 405 | $5K | |
| 80076 | <1% | 836 | $4K | |
| 83880 | <1% | 207 | $4K | |
| 85652 | <1% | 2,106 | $4K | |
| 73630 | <1% | 311 | $3K | |
| 86780 | <1% | 298 | $3K | |
| 84145 | <1% | 211 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 53 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 751 | $3K |
| 84460 | <1% | 908 | $3K | |
| 84450 | <1% | 909 | $3K | |
| 80051 | <1% | 659 | $3K | |
| 82607 | <1% | 274 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 40 | $2K |
| 85379 | <1% | 319 | $2K | |
| 84520 | <1% | 875 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 200 | $2K |
| 87081 | <1% | 304 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 60 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $1K |
| 97014 | <1% | 53 | $1K | |
| 87807 | <1% | 100 | $1K | |
| 72110 | <1% | 18 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 21 | $1K |
| 82310 | <1% | 386 | $1K | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 20 | $870.10 |
| 82570 | <1% | 309 | $791.98 | |
| 82043 | <1% | 265 | $777.99 | |
| 82550 | <1% | 242 | $738.91 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 54 | $615.76 |
| 77003 | <1% | 220 | $581.44 | |
| 80069 | <1% | 131 | $547.75 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 15 | $367.20 |
| 82746 | <1% | 49 | $356.88 | |
| 86850 | <1% | 81 | $355.05 | |
| 87150 | <1% | 13 | $321.46 | |
| 87070 | <1% | 55 | $292.72 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15 | $264.88 |
| 82785 | <1% | 17 | $181.06 | |
| 86803 | <1% | 15 | $156.97 | |
| 87077 | <1% | 31 | $145.44 | |
| 86901 | <1% | 54 | $140.95 | |
| 83615 | <1% | 51 | $126.95 | |
| 83550 | <1% | 37 | $120.59 | |
| 86900 | <1% | 42 | $114.13 | |
| 87340 | <1% | 15 | $100.83 | |
| 83540 | <1% | 37 | $89.27 | |
| 86592 | <1% | 47 | $51.63 | |
| 82947 | <1% | 47 | $48.58 | |
| 86308 | <1% | 13 | $46.62 | |
| 84156 | <1% | 30 | $29.61 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 3,429 | $25.22 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,938 | $20.07 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,297 | $9.10 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,201 | $1.87 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,407 | $1.40 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 57 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 247 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,200 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 61 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 533 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 74 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 132 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 85 | $0.00 |
| 87205 | 0% | 22 | $0.00 | |
| 82962 | 0% | 21 | $0.00 | |
| C1769 | Guide wire | 0% | 29 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 1,209 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 177 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 676 | $0.00 |
| 84425 | 0% | 12 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 113 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 160 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 123 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 20 | $0.00 |
| J1096 | Dexamethasone, lacrimal ophthalmic insert, 0.1 mg | 0% | 64 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKULLERSTRAND, CHAR (REGIONAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| ST Catherine Hospital INC | East Chicago, IN | $32.25M |
| Munster Medical Research Foundation INC | Munster, IN | $23.67M |
| ST Catherine Hospital INC | East Chicago, IN | $198K |
| Munster Medical Research Foundation INC | Munster, IN | $50K |
| ST Mary Medical Center INC | Hobart, IN | $19K |
| Community Stroke and Rehabilitation Center INC | Crown Point, IN | $3K |
| ST Catherine Hospital INC | East Chicago, IN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.